Trump Administration Negotiates Drug Pricing Deals with Smaller Pharmaceutical Companies

The Trump administration is negotiating drug-pricing agreements with smaller biotechnology companies in April 2026, threatening 100% tariffs on imported medicines as leverage. These talks extend a strategy previously used with larger drugmakers, where the administration extracted voluntary, confidential commitments for lower prices and increased domestic manufacturing. Smaller pharmaceutical companies, previously excluded from initial negotiations, can now pledge pricing concessions to potentially avoid tariffs or new Medicare pricing policies. The negotiations offer these companies greater certainty about federal policy impacts while allowing the administration to expand its drug pricing initiative beyond major pharmaceutical firms.

White House negotiations with smaller pharmaceutical companies

• ▪The Trump administration's new drug-pricing talks offer a pathway for smaller pharmaceutical companies not included in the first round of deals.
• ▪Smaller pharmaceutical companies have faced substantial uncertainty about how federal policies would affect them prior to the Trump administration's new negotiations.
• ▪Smaller pharmaceutical companies in the Trump administration negotiations can pledge lower prices to potentially avoid tariffs or new pricing policies through Medicare.
• ▪The Trump administration's negotiations with smaller pharmaceutical companies offer these companies the chance to gain more certainty about how federal policies might affect them.
• ▪The Trump administration is negotiating new drug-pricing deals with smaller pharmaceutical companies as of April 2026.

Strategy replication from larger drugmaker deals

• ▪The Trump administration's strategy with larger drugmakers involved extracting voluntary, confidential agreements in pursuit of lower prices and more domestic manufacturing.
• ▪The Trump administration's new negotiations with smaller pharmaceutical companies suggest the administration is looking to replicate the strategy it used with larger drugmakers.
• ▪The Trump administration conducted a first round of drug-pricing deals with larger pharmaceutical companies prior to April 2026.

Tariff threats and policy uncertainty for smaller firms

• ▪Small drugmakers faced a tariff threat that prompted negotiations with the White House on pricing deals.
• ▪Smaller pharmaceutical companies can potentially avoid tariffs through the Trump administration's new drug-pricing negotiations.

Perspective of Smaller biotechnology companies

• ▪Smaller biotechnology companies face the threat of 100% tariffs on imported medicines from the Trump administration as of April 2026.
• ▪Smaller biotechnology companies view the Trump administration's drug-pricing negotiations as a way to secure protection from uncertain federal policies.

Perspective of Trump Administration

• ▪The Trump administration aims to increase domestic manufacturing of medicines through its drug-pricing negotiations with pharmaceutical companies.
• ▪The Trump administration is using the threat of 100% tariffs on imported medicines as leverage in drug-pricing negotiations with smaller pharmaceutical companies.
• ▪The Trump administration seeks to extract voluntary confidential agreements from smaller pharmaceutical companies similar to deals made with larger drugmakers.

1 source